Intensive Postremission Chemotherapy in Adults with Acute …
网页1994年10月6日 · We treated 1088 adults with newly diagnosed AML with three days of daunorubicin and seven days of cytarabine and randomly assigned patients who had a complete remission to receive four courses of...
Post-remission therapy for acute myeloid leukemia - PMC
网页2014年7月23日 · Post-remission therapies with high-dose cytarabine, autologous and allogeneic HSCT have been evaluated with the aim of preventing relapse and of improving overall survival. To date, allogeneic HSCT is considered to be the intensive post-remission therapy with the strongest anti-leukemic effect.
Postremission cytopenia management in patients with acute …
网页Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol. 2022 Nov;97 (11):E416-E419. doi: 10.1002/ajh.26692. Epub 2022 Sep 16. Authors.
Post-remission therapy for acute myeloid leukemia in younger …
网页Post-remission therapy aims to destroy leukemia cells that survived induction chemotherapy but are undetectable by conventional studies. There are three basic options for post-remission therapy (in order of increasing intensity): consolidation chemotherapy, autologous hematopoietic cell transplantation (HCT), or allogeneic HCT.
Novel postremission strategies in adults with acute myeloid …
网页Given the high rates of relapse in acute myeloid leukemia (AML), there is tremendous opportunity for the development of new therapeutic strategies in the postremission state. Unfortunately, the currently available modalities for postremission therapy, namely chemotherapy, have proven largely ineffective in changing the natural history of AML.
Post-remission therapy in acute myeloid leukemia: Are we ready …
网页Recent advances in remission induction treatment strategies for acute myeloid leukemia (AML) have improved the rates of complete remission (CR) and overall survival (OS), owing to a concerted effort to tailor therapies toward specific AML subtypes.
Intensive postremission chemotherapy in adults with acute …
网页1994年10月6日 · Abstract. Background: About 65 percent of previously untreated adults with primary acute myeloid leukemia (AML) enter complete remission when treated with cytarabine and an anthracycline. However, such responses are rarely durable when conventional postremission therapy is administered.
American Journal of Hematology - Wiley Online Library
网页2022年8月30日 · Postremission cytopenia events after initial count recovery were grade 4 neutropenia or thrombocytopenia lasting ≥7 days. Grade 4 neutropenia was defined as the occurrence of an ANC <500/μL, and grade 4 thrombocytopenia with occurrence of a platelet count <25 × 10 3 /μL.
Varying Intensity of Postremission Therapy in Acute Myeloid …
网页1992年4月15日 · Postremission therapy began 4 weeks after CR if patients had a performance status of 0 or 1 (ECOG scale), no persisting infection, and adequate renal (creatinine <2 mg/dL) and hepatic (serum alkaline phosphatase <2x normal, transaminases <4x normal, and bilirubin <2 mg/dL) function.
Postremission treatment of elderly patients with acute myeloid …
网页2007年6月15日 · Advances in the treatment of younger patients with acute myeloid leukemia (AML) have been obtained with intensified postremission treatments, such as high-dose chemotherapy or allogeneic stem cell transplantation. 1,2 However, approximately half of patients with newly diagnosed AML are older than 65 years and thus are not eligible for such ...
跳至内容